A Cat is Not a Dog: Specific Therapeutic Considerations World Small Animal Veterinary Association World Congress Proceedings, 2007

Similar documents
Irish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen

Commonly Used Analgesics

Non-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without

Just where it s needed.

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

Metacam 1.5 mg/ml oral suspension for dogs

- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

SUMMARY OF PRODUCT CHARACTERISTICS

Veterinary Medicinal Product

Pain Management in Racing Greyhounds

Irish Medicines Board

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

POST-OPERATIVE ANALGESIA AND FORMULARIES

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats

SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Providing Constant Analgesia with OROS Ò Hydromorphone

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

SUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

Research update - medicines for koalas

Oral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.

Dexmedetomidine and its Injectable Anesthetic-Pain Management Combinations

Start of new generation of NSAIDs?

Veterinary Pharmacy An Introduction Jennifer A. Kelleher, PharmD, BCPS, FSVHP Compounding Pharmacist

Summary of Product Characteristics

Sea Turtle Analgesics Selection - NSAIDS. Loggerhead Coquina (postoperative ketorolac)

Only for Intravenous Use in Beef and Dairy Cattle. Not for Use in Dry Dairy Cows and Veal Calves. For Intravenous or Intramuscular Use in Horses.

Summary of Product Characteristics

Summary of Product Characteristics

ISMP Canada HYDROmorphone Knowledge Assessment Survey

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

APOQUEL 3.6 MG TABLETS FOR DOGS / KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS BEFORE OPENING OR USING

Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods

SUMMARY OF PRODUCT CHARACTERISTICS

Ylva Sjöström 1) and Anna Lennquist 2)

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Final Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014

Please refer to Table 1 Dosage and Treatment Schedule TABLE 1 Species Product Number of Tubes Cats. Rabbits or Advantage 40 for Cats

EPAR type II variation for Metacam

Part 1 : General multiple-choice questions

SUMMARY OF PRODUCT CHARACTERISTICS

Mouse Formulary. The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed.

Irish Medicines Board

Curricular Components for Infectious Diseases EPA

HEARTWORM DISEASE AND THE DAMAGE DONE

SUMMARY OF PRODUCT CHARACTERISTICS. Excipients: Contains 4% w/w cetyl alcohol and 7% w/w propylene glycol.

SUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)

Treating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

RENAL CLEARANCE OF CARPROFEN IN THE ISOLATED PERFUSED RAT KIDNEY

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

SUMMARY OF PRODUCT CHARACTERISTICS

Principles of Antimicrobial therapy

Tablet. A light-brown to brown, meat flavoured, bone shaped tablet scored on both sides that can be divided into halves.

SUMMARY OF PRODUCT CHARACTERISTICS

Introduction to Antimicrobial Therapy

Tautopathic Treatment. Systemic infection or localized infections

Anesthesia Check-off Form

Introduction to Antimicrobial Therapy

Dosing Your Cat with Azithromycin Pediatric Suspension. By Lorraine Shelton

Oral sedation of horses

Discover the. Discover the. innovative science. Veraflox (pradofloxacin) Veraflox. Efficacy. Safety. Ease-of-use.

SUMMARY OF PRODUCT CHARACTERISTICS

NSAIDs: the Past, Present, and Future

SUMMARY OF PRODUCT CHARACTERISTICS

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*

The world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF

EMEDOG 1mg/ml Solution for injection for dogs. Part I ADMINISTRATIVE DATA AND SUMMARY OF THE DOSSIER

Dose-related thermal antinociceptive effects of intravenous hydromorphone in cats

folate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole

Welcome to. Who Wants to be a Millionaire 50:50

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Non-steroidal anti-inflammatory drugs in dogs and cats what s new?

American Association of Feline Practitioners American Animal Hospital Association

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1

Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs

Pharmacology Week 6 ANTIMICROBIAL AGENTS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

A Cat is Not a Dog: Specific Therapeutic Considerations World Small Animal Veterinary Association World Congress Proceedings, 2007 Hervé P. Lefebvre, DVM, PhD, DECVPT; Brice Reynolds, DVM UMR 181 Physiopathologie et Toxicologie Experimentales INRA, ENVT and Department of Clinical Sciences, National Veterinary School Toulouse, France In the past, cats have been treated very often as if they were small dogs. However, cats and dogs are quite different species regarding therapeutic considerations because of biological/physiological but also psychological differences. The cat is generally considered as a more difficult species in terms of handling and drug administration than the dog. Analgesics tend to be less frequently prescribed in cats than in dogs after traumatic injury (Armitage et al, 2005). Therapeutic management of a feline patient should be based on specific considerations. Although major differences exist between cats and dogs in drug safety and toxicology, only pharmacokinetics and pharmacodynamics will be considered here. Choice of Formulations and Route of Administration Oral formulation--oral administration is a very convenient route for treatment of chronic diseases. Swallowing of liquid formulations is easier than that of tablets. For tablets, small-size tablets are needed. The tablet can be inserted in some appetent food (fish or liver). The broken surface a secable tablet should be covered with butter to mask the taste of the medication. After tablet administration, a water bolus is recommended to facilitate oesophageal transit (Westfall et al, 2001). This procedure may prevent oesophageal stricture or oesophagitis observed with some caustic compounds (e.g., doxycycline) and due to oesophageal retention of the tablet. Because of the greater issue in dosing cats, palatable feline formulations represent a current challenge for drug industries. A taste which is desirable in dogs and humans does not make it desirable to feline patients. For example, cats did not like the taste of some sweeteners like saccharin, but are highly responsive to amino acids. Cats exhibit no preference for salt solutions over tap water (Thombre, 2004). Medications are sometimes smeared onto fur for ingestion during self-grooming but such an approach is not appropriate. Injectable formulation--when possible, intravenous administration should be preferred in cats. Feline post-vaccinal fibrosarcomas due to

subcutaneous inflammatory reactions at sites of injection have been largely described over the last decade and are mainly associated with the injection of inactivated virus vaccines containing aluminium-based adjuvants (Hendrick, 1998). The practitioner should be aware that administration-induced stress can affect blood glucose, but also neutrophil, eosinophil, and lymphocytes counts. Pharmacokinetic Differences Between Cats and Dogs Absorption Oral absorption may differ between cats and dogs because of gastrointestinal anatomical and physiological differences. The absolute gastric and intestinal volumes are larger in the dog. The relative volumes of the stomach and large intestine are similar, but the relative size of the feline small intestine is shorter than that of the dog. In fasting conditions, beads (1.5-5 mm) empty similarly from the stomach in dogs and cats. In the fed state, their residence time is higher in the stomach of the cat. A delay in gastric emptying may alter drug absorption. Gradual emptying of drug into the duodenum may indeed allow the complete dissolution of the total dose (Sutton, 2004). The small intestinal transit times of small beads was reported slightly longer in the cat than in the dog (Chandler et al, 1997). The small intestinal permeability may be different in cats compared to dogs. For lactulose, it is 3-4 times higher in cats than in dogs (Johnston et al, 2001). For ciprofloxacin, the mean oral bioavailability in dogs approximate 40% whereas in cats, it was 0-20% (Albarellos et al, 2004). Oral formulations of selamectin show a higher bioavailability in cats (109%) compared to dogs (62%) (Sarasola et al, 2002). This may result from lower P-glycoprotein concentrations in the cat. Oral mucosal administration has been also proposed in cats as an alternative for injections. For buprenorphine, the maximal concentration was observed 15 min after dosing. The oral bioavailability by this route is 100%. This high value by comparison with other species could be explained by the alkaline ph (8 to 9) of the cat's mouth, as buprenorphine is a weak base. The same study demonstrated that most of the owners consider this route highly acceptable or acceptable (Robertson et al, 2003). Topical formulations may be also absorbed quite differently between cats and dogs because the cats skin appears to be thinner than the dog skin (Monteiro-Riviere et al, 1990). For example, the bioavailability of topical formulations of selamectin in cats (74%) was higher than that in dogs (4.4%), which could be explained by greater transdermal flux (Sarasola et al, 2002). After fentanyl transdermal patch placement, cats achieve steady

state plasma concentration faster than dogs (6-12 h vs 18-24 h) (Riviere and Papich, 2001). Distribution Total body water contents in dogs and cats are very similar (66 and 64%, respectively) (Culebras et al, 1977). Differences in drug distribution between dogs and cats may also exist although underlying mechanisms remain unknown. For example, doxycycline is more extensively bound to serum proteins of cats (98%) than to those of dogs (91%). Binding to feline albumin is also more important (76 vs 54%). Volume of distribution of doxycycline was approximately 3 times lower in cats (340 ml/kg) than in dogs (930 ml/kg) (Riond et al., 1990). Metabolism Drug metabolism represents the most important pharmacokinetic difference between cats and dogs. Cats are relatively deficient in their ability to conjugate xenobiotics with glucuronic acid, and consequently the clearance of drugs which biotransformation depends mainly on glucuronidation is decreased and half-life is prolonged. Recently, a molecular genetic basis for this deficiency has been identified (Court and Greenblatt, 2000). Such a deficiency explains the feline susceptibility to the toxic effects of phenolic drugs (e.g., paracetamol) and delayed elimination of other drugs such as aspirin (its half-life is about 37.6 h in cats and 8.6 h in dogs) or carprofen (the half-life of carprofen in cats is 20 h (Taylor et al, 1996), twice that of the dog). Morphine also is poorly biotransformed in cats in morphine-6 glucuronide, a metabolite with analgesic properties, which explains that morphine appears to be less effective in cats than in other species. Inversely, acetylation is deficient in dogs but apparently not in cats, and clearance of drugs which metabolism depends on acetylation is higher in cats than in dogs (e.g., hydralazine, diltiazem) (Boothe, 1990). Renal and Biliary Elimination Renal elimination may also differ. Creatinine is essentially cleared by glomerular filtration in both species and therefore an indicator of glomerular filtration rate. Its plasma clearance in cats (about 2.3 ml/min/kg (Le Garreres et al, 2007)) however is smaller than that in small-breed dogs (3.5-4 ml/min/kg). As both species are carnivorous, the urine ph is very similar and acid. Consequently, interspecies difference in tubular reabsorption according to the pka of the drug is probably of limited importance. Bromide is also essentially cleared by the kidney but its elimination half-life in cats is approximately one third (1.6 weeks) of that reported in dogs (5.3 weeks) (Boothe et al, 2002). In contrast, prevalence of

adverse effects (especially bronchial asthma) seems to be higher in cats and bromide appears not to be a safe drug to use in cats. Biliary excretion is not well documented in cats. Sulfobromophthalein and indocyanine green clearances are higher in cats than in dogs (Center et al, 1983). Pharmacodynamic Differences Pharmacodynamics may differ independently of pharmacokinetic differences. The example of morphine is well known in small animal pharmacology. It causes CNS stimulation and pupillary dilation in cats, contrary to what is observed in dogs. Because of mydriasis, the cat should be approached very slowly and kept away from bright light. Excitation at the dose currently recommended (0.1-0.2 mg/kg) is extremely rare. Furosemide efficacy is different between cats and dogs. A dose of 0.625 mg/kg is effective in the dog but not the cat. Urine potassium excretion was relatively dose-independent in the cat, whereas it increases in dogs with increasing doses (Klatt et al, 1975). Specific dosage regimen should be defined for the feline and canine patients in conditions such as congestive heart failure. Differences in response to isoflurane for dogs and cats were also described (Steffey and Howland, 1977). Conclusion Dosage regimen in small dogs should not be extrapolated to cats. Specific information in pharmacokinetics but also pharmacodynamics is still needed for many drugs used in feline medicine. References 1. Albarellos GA, Kreom VE, Landoni MF. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. J Vet Pharmacol Ther 2004;27:155-162. 2. Armitage EA, Wetmore LA, Chan DL. Evaluation of compliance among nursing staff in administration of prescribed analgesic drugs to critically ill dogs and cats. J Am Vet Med Assoc 2005;227:425-429. 3. Boothe DM. Drug therapy in cats: mechanisms and avoidance of adverse drug reactions. J Am Vet Med Assoc 1990;196:1297-1305. 4. Boothe DM, George KL, Couch P. Disposition and clinical use of bromide in cats. J Am Vet Med Assoc 2002;221:1131-1135.

5. Center SA, Bunch SE, Baldwin BH, et al. Comparison of sulfobromophthalein and indocyanine green clearances in the cat. Am J Vet Res 1983;44:727-730. 6. Court M, Greenblatt D. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics 2000;10:355-369. 7. Culebras JM, Fitzpatrick GF, Brennan MF, et al. Total body water and the exchangeable hydrogen II. A review of comparative data from animals based on isotope dilution and desiccation with a report of new data from the rat. Am J Physiol 1977;232:R60-R65. 8. Johnston KL, Ballevre OP, Batt RM. Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats. Am J Vet Res 2001;62:111-118. 9. Chandler M, Guilford G, Lawoko C. Radioopaque markers to evaluate gastric emptying and small intestine transit time in healthy cats. J Vet Intern Med 1997;11:361-364. 10. Hendrick MJ. Historical review and current knowledge of risk factors involved in feline vaccine-associated sarcomas. J Am Vet Med Assoc 1998;213:1422-1423. 11. Klatt P, Muschaweck R, Bossaller W, et al. Method of collecting urine and comparative investigation of quantities excreted by cats and dogs after administration of furosemide. Am J Vet Res 1975;36:919-923. 12. Le Garreres A, Laroute V, De La Farge F, et al. Disposition of plasma creatinine in non-azotaemic and moderately azotaemic dogs. J Fel Med Surg 2007, in press. 13. Monteiro-Riviere NA, Bristol DG, Manning TO, et al. Interspecies and interregional analysis of the comparative thickness and laser Doppler blood flow measurements of five cutaneous sites in nine species. J Invest Dermatol 1990;58:582-586. 14. Riond JL, Vaden SL, Riviere JE. Comparative pharmacokinetics of doxycycline in cats and dogs. J Vet Pharmacol Ther 1990;13:415-424. 15. Riviere J, Papich M. Potential and problems of developing transdermal patches for veterinary applications. Adv Drug Delivery Rec 2001;50:175-203.

16. Robertson SA, Taylor PM, Sear JW. Systemic uptake of buprenorphine by cats after oral mucosal administration. Vet Rec 2003; 31:675-678. 17. Sarasola P, Jernigan AD, Walker DK, et al. Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. J Vet Pharmacol Ther 2002;25:265-272. 18. Steffey EP, Howland D. Isoflurane potency in the dog and cat. Am J Vet Res 1977;38:1833-1836. 19. Sutton SC. Companion animal physiology and dosage form performance. Adv Drug Deliv Rev 2004;56:1383-1398. 20. Taylor P, Delatour P, Landoni F, et al. Pharmacodynamics and enantioselective pharmacokinetics of carprofen in cats. Res Vet Sci 1996;60:144-151. 21. Thombre AG. Oral delivery of medications to companion animals: palatability considerations. Adv Drug Deliv Rev 2004;56:1399-1413. Speaker Information (click the speaker's name to view other papers and abstracts submitted by this speaker) Hervé P. Lefebvre, DVM, PhD, DECVPT National Veterinary School of Toulouse France Brice Reynolds, DVM National Veterinary School of Toulouse France